Search

Cubosomes have aroused growing interest recently due to their widespread applications in pharmaceutical, food, cosmetic industries, etc. Especially, they demonstrate many advantages as drug delivery systems. However, no pharmaceutical products have been translated from bench to bedside so far. To promote the translation of the drug delivery system candidate, it is significant to accumulate fundamental and applied-fundamental knowledge of cubosomes. In the study, a bibliometric study upon cubosome research was carried out on the basis of Web of Science Core Collection database to figure out current and evolving knowledge domains of the published studies in a logical and robust way, summarizing the status quo and pointing out the future directions of cubosome research. Four questions which are pending addressed were answered by applying this research method and some conclusions were drawn: (1) Australia could be viewed as the most productive contributor for cubosome research. (2) Langmuir might be the most influential publishing media. (3) Using cubosomes as drug delivery carriers was a hot topic. (4) Adopting cubosomes as ocular drug delivery vehicles would continue to be a frequently studied aspect. In addition, cubosomes serve as alternative vector deliver active pharmaceutical ingredients to the brain and encapsulate active components extracted from herbal and traditional medicines in cubosomes are the burgeoning trends. By answering the four questions, productive contributors, influential publishing media, current research foci, and future directions were figured out. Hence, the current and evolving knowledge domains of cubosome studies were illustrated. [ABSTRACT FROM AUTHOR]

Purpose: Contention surrounds how best to screen patients for latent and undiagnosed infection prior to cancer treatment. Early treatment and prophylaxis against reactivation may improve infection-associated morbidity. This study sought to examine rates of screening and prevalence of latent infection in overseas-born patients receiving cancer therapies. Methods: A single-centre retrospective audit of 952 overseas-born patients receiving chemotherapy, targeted agents and immunotherapy between January 1 and December 31 2019 was undertaken at Peter MacCallum Cancer Centre. Pre-treatment screening for hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV), latent tuberculosis (LTBI), toxoplasmosis and strongyloidiasis was audited. Results: Approximately half of our overseas-born patients were screened for HBV (58.9%) and HCV (50.7%). Fewer patients were screened for HIV (30.5%), LTBI (18.3%), strongyloidiasis (8.6%) or toxoplasmosis (8.1%). Although 59.7% of our patients were born in countries with high epidemiological risk for latent infection, according to World Health Organization data, 35% were not screened for any infection prior to commencement of therapy. Conclusion: The prevalence of latent infections amongst overseas-born patients with cancer, and complexities associated with risk-based screening, likely supports universal latent infection screening amongst this higher-risk cohort. [ABSTRACT FROM AUTHOR]